Results 91 to 100 of about 2,602 (175)
A public health approach to hepatitis C control in low- and middle-income countries. [PDF]
, 2015 In light of new treatment regimens for hepatitis C, Amitabh Suthar and Anthony Harries outline a wider public health approach for tackling the ...
Harries, Anthony D, Suthar, Amitabh B
core +2 more sources
CPT: Pharmacometrics &Systems Pharmacology, Volume 13, Issue 1, Page 118-131, January 2024.Abstract Hepatic impairment (HI) moderately (<5‐fold) affects the systemic exposure (i.e., area under the plasma concentration–time curve [AUC]) of drugs that are substrates of the hepatic sinusoidal organic anion transporting polypeptide (OATP) transporters and are excreted unchanged in the bile and/or urine.
Flavia Storelli +7 more
wiley +1 more source
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods [PDF]
, 2015 HepatitisCvirus(HCV)is classified into seven major genotypesand67 subtypes. Recent studies haveshownthat inHCVgenotype 1-infected patients, response rates to regimens containingdirect-acting antivirals(DAAs)are subtype dependent.
Allende, Helena +41 more
core +2 more sources
Acta Pharmaceutica Sinica B, 2016 Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A ...
Xingquan Zhang
doaj +1 more source
Antiviral activity of organic molecules having sulfonamide moiety: An insight of recent research [PDF]
, 2018 Sulfonamide derivatives are well known for their antibacterial activity as manifested by ‘Sulfa Drugs’, for example, sulfamethoxazole etc. In addition, they are associated with a large number of pharmacological activities such as anti-microbial, anti ...
Aslam, S. +4 more
core +1 more source
Противовирусные лекарственные средства для лечения гепатита C [PDF]
, 2019 ГЕПАТИТ C /ЛЕК ТЕРПАРЕНТЕРАЛЬНО-ПЕРЕДАВАЕМЫЙ ГЕПАТИТ НИ-A, НИ-B /ЛЕК ТЕРПРОТИВОВИРУСНЫЕ СРЕДСТВА /ХИМЛЕКАРСТВ ХИМИЧЕСКАЯ СТАБИЛЬНОСТЬИНГИБИТОРЫ ПРОТЕАЗЫ NS3/NS4АИНГИБИТОРЫ БЕЛКА NS5AИНГИБИТОРЫ NS5B ПОЛИМЕРАЗЫДан обзор химической структуры и её связи с ...
Жерносек, А. К. +1 more
core
Current status and future directions in the management of chronic hepatitis C [PDF]
, 2012 Hepatitis C virus (HCV) is endemic worldwide, and it causes cirrhosis and other complications that often lead to death; nevertheless, our knowledge of the disease and its mechanisms is limited. HCV is most common in underdeveloped nations, including many
Wosen Aman +3 more
core +2 more sources
BMC Nephrology, 2017 Background Direct-acting antivirals (DAAs) dramatically improve the treatment of hepatitis C virus (HCV) infections. However, the effects of DAAs on extra-hepatic manifestations such as HCV-associated glomerulonephritis, especially in cases with renal ...
Michiko Shimada +7 more
doaj +1 more source
Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions [PDF]
, 2016 Organic anion transporting polypeptide (OATP) 1B1 mediates the hepatic uptake of many drugs including lipid-lowering statins. Decreased OATP1B1 transport activity is often associated with increased systemic exposure of statins and statin-induced myopathy.
Abuznait, Alaa H. +7 more
core +2 more sources
Gut and Liver, 2018 Background/AimsChanges in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years.
Takeshi Chida +10 more
doaj +1 more source